Towa Pharmaceutical Co., Ltd.
4553.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | ¥18,986,000 | ¥16,173,000 | ¥4,605,000 | ¥22,246,000 |
| Dep. & Amort. | ¥20,099,000 | ¥17,888,000 | ¥19,409,000 | ¥10,954,000 |
| Deferred Tax | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock-Based Comp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Change in WC | -¥10,530,000 | -¥26,944,000 | -¥13,747,000 | -¥3,102,000 |
| Other Non-Cash | -¥5,154,000 | ¥1,095,000 | -¥7,723,000 | -¥7,969,000 |
| Operating Cash Flow | ¥23,401,000 | ¥8,212,000 | ¥2,544,000 | ¥22,129,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -¥31,223,000 | -¥37,851,000 | -¥30,469,000 | -¥13,576,000 |
| Net Acquisitions | ¥9,000 | -¥1,570,000 | -¥1,484,000 | -¥45,405,000 |
| Inv. Purchases | -¥203,000 | -¥50,000 | -¥301,000 | -¥1,000 |
| Inv. Sales/Matur. | ¥0 | ¥0 | ¥34,000 | ¥18,000 |
| Other Inv. Act. | ¥130,000 | -¥923,000 | ¥1,936,000 | -¥765,000 |
| Investing Cash Flow | -¥31,287,000 | -¥40,394,000 | -¥30,284,000 | -¥59,729,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | ¥24,497,000 | ¥38,560,000 | ¥20,883,000 | ¥49,114,000 |
| Stock Issued | ¥0 | ¥0 | ¥0 | ¥21,000 |
| Stock Repurch. | ¥0 | ¥0 | ¥0 | ¥0 |
| Dividends Paid | -¥2,953,000 | -¥2,952,000 | -¥3,100,000 | -¥2,411,000 |
| Other Fin. Act. | ¥23,000 | -¥201,000 | -¥302,000 | -¥184,000 |
| Financing Cash Flow | ¥21,567,000 | ¥35,407,000 | ¥17,481,000 | ¥46,540,000 |
| Forex Effect | ¥1,916,000 | ¥2,167,000 | ¥1,685,000 | ¥975,000 |
| Net Chg. in Cash | ¥15,810,000 | ¥5,393,000 | -¥8,573,000 | ¥9,915,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | ¥29,650,000 | ¥24,257,000 | ¥32,830,000 | ¥22,915,000 |
| End Cash | ¥45,471,000 | ¥29,650,000 | ¥24,257,000 | ¥32,830,000 |
| Free Cash Flow | -¥5,335,000 | -¥31,113,000 | -¥27,925,000 | ¥8,553,000 |